A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Loki zupa in Patients With Chronic Asthma

Frontiers in Pharmacology
Yubao LvJingcheng Dong

Abstract

The purpose of this study was to evaluate the efficacy and safety of Uyghur medical formula Loki zupa in patients with chronic asthma. Adult patients with chronic asthma randomly received placebo or Loki zupa as add-on to inhaled corticosteroids (ICS) maintenance treatment. Loki zupa or mimics was administered orally 10 ml per time, three times a day for 8 weeks. The primary endpoints were asthma control test (ACT) score and peak expiratory flow (PEF). The secondary endpoints were acute exacerbation rate, lung function, night waking days, and symptom-free days in the near 2 weeks, Asthma Quality of Life Questionnaire (AQLQ) score and some inflammatory cytokines in peripheral blood. A total of 240 adult patients with chronic asthma were enrolled, and 218 patients were randomized to placebo (n = 109) or Loki zupa (n = 109) in addition to ICS for 8 weeks. Treatment with Loki zupa resulted in significant improvement in ACT score compared to the placebo group (p = 0.002). Furthermore, oral taken of Loki zupa increased the PEF obviously (p = 0.026). Loki zupa treatment did not improve the forced expiratory volume in 1 s (FEV1, p = 0.131) and FEV1/FVC compared to the placebo treatment (p = 0.805). The placebo group had higher rates of...Continue Reading

References

Jun 3, 2009·Pulmonary Pharmacology & Therapeutics·Masafumi YamaguchiMichiaki Mishima
Mar 17, 2010·Immune Network·Hiroshi Nakajima, Koichi Hirose
Apr 16, 2011·American Journal of Respiratory Cell and Molecular Biology·Pingli WangStephania A Cormier
Jun 11, 2011·Primary Care Respiratory Journal : Journal of the General Practice Airways Group·Martyn R PartridgeDario Olivieri
Sep 20, 2011·Pharmacology & Therapeutics·Hiroichi Nagai
May 4, 2013·Current Opinion in Pharmacology·Stephen T Holgate
Mar 14, 2014·The Lancet. Respiratory Medicine·Heidi MakriniotiSebastian L Johnston
Dec 3, 2014·Pharmacology & Therapeutics·Louise M HarknessJanette K Burgess
Mar 10, 2015·The Journal of Allergy and Clinical Immunology·Timothy S C HinksRatko Djukanović
Jan 16, 2016·Therapeutic Advances in Chronic Disease·Leena George, Christopher E Brightling
Mar 30, 2016·The Journal of Allergy and Clinical Immunology. in Practice·Terufumi ShimodaTomoaki Iwanaga

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA
blood collection

Software Mentioned

SAS

Related Concepts

Related Feeds

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.